Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT06803602Enrolling by invitation
Magnetic therapy for urine leaks after prostate surgery
This trial tests a non-invasive magnetic treatment (HIFEM) to help men with urine leaks after prostate cancer removal (radical prostatectomy) or HoLEP surgery. The goal is to see if it improves bladder control and quality of life.
Scottsdale, ArizonaAges 18–100 - NCT05882253Recruiting
Test MRI-guided biopsy for early prostate cancer detection
This study uses a special MRI-guided (MRI-fusion) needle biopsy to look for early prostate cancer. It may help find concerning areas more accurately before cancer spreads.
La Jolla, CaliforniaAges Any age - NCT06769997Recruiting
Comparing Optilume and Rezum for enlarged prostate
This study compares two treatments for an enlarged prostate: Optilume (a catheter-based system) and Rezum (water vapor therapy). It's for men with moderate symptoms who haven't tried other treatments before.
Montreal, QuebecAges 18 years+ - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Colorado Springs, ColoradoAges 18 years+ - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06773806Recruiting
Chlordecone exposure and prostate cancer in Martinique
This trial studies whether exposure to the pesticide chlordecone affects prostate cancer risk in men living in Martinique. It compares men newly diagnosed with prostate cancer to those without cancer.
Fort-de-FranceAges 18–75 - NCT06772441RecruitingPhase 2
AI-guided radiation and hormone therapy for high-risk prostate cancer
This trial uses artificial intelligence to customize your radiation therapy and hormone treatment for high-risk prostate cancer. It aims to improve treatment precision and reduce side effects.
LimassolAges 18 years+ - NCT06759701RecruitingEarly Phase 1
Weight loss drug before prostate cancer surgery pilot study
This study tests if taking tirzepatide (a weight loss medicine) before prostate removal surgery is safe and helpful for overweight men with intermediate-risk prostate cancer. It aims to see if losing weight can improve surgery outcomes.
Houston, TexasAges 18 years+ - NCT03830788Recruiting
Radiation options for early prostate cancer-related erections
This study compares two radiation treatments—seed brachytherapy and stereotactic body radiotherapy—to see which better preserves erections in men with early- to mid-risk prostate cancer. It’s designed to help patients understand how different curative radiation choices can affect sexual function.
AlbiAges 18 years+ - NCT06723665Enrolling by invitation
PET/CT scan for prostate cancer patients
This study uses a special type of PET/CT scan called 18F-PSMA-1007 to take detailed pictures of prostate cancer. It's for people who might have prostate cancer, have been diagnosed, or need to check how their cancer is doing after treatment.
Wuxi, JiangsuAges 40–75 - NCT05885009Recruiting
Liquid biopsy test to guide treatment in metastatic prostate cancer
This study looks at using a simple blood test (liquid biopsy) to read tumor DNA and understand how it could affect treatment decisions. It is for adults with metastatic prostate cancer who are about to start, are receiving, or recently finished treatment.
BarcelonaAges 18 years+ - NCT06714630Recruiting
Study Learning from Men Treated for Prostate Cancer
This trial looks at long-term results after radiation therapy for prostate cancer. By studying PSA test results and imaging scans from men who were treated at least 10 years ago, researchers hope to learn more about side effects and how well the treatment worked over time.
Edinburgh, LothianAges Any age - NCT06700057Recruiting
Study of lutetium treatment for prostate cancer
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
BordeauxAges 18 years+ - NCT06687421Recruiting
Precision medicine for high-risk prostate cancer
This study aims to use precision medicine (tailored treatment based on your specific cancer) for men at high risk of prostate cancer. It may help doctors choose the best treatment for you.
UmeåAges 18 years+ - NCT06220435Recruiting
Radiation therapy for very high-risk localized prostate cancer
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
LundAges 18 years+ - NCT06690970Recruiting
PSMA PET/CT scan for people with or suspected to have cancer
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
Hefei, AnhuiAges 18–80 - NCT06689514RecruitingEarly Phase 1
Tranilast for enlarged prostate (medium to large volume)
This trial tests a drug called Tranilast to see if it can improve urinary symptoms caused by an enlarged prostate. It focuses on men with moderate to severe symptoms and a prostate size greater than 40 mL.
Shanghai, Outside U.S./CanadaAges 55–75 - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT06672926Recruiting
New Prostate MRI Pathway for Radiographers
This trial tests a new way for experienced MRI radiographers to review prostate MRI scans, aiming to improve the diagnostic pathway for prostate cancer. It may help patients by leading to faster and more accurate results.
Stoke-on-Trent, StaffordshireAges Any age - NCT06668142Recruiting
Beacon platform study for prostate surgery
This trial tests a new surgical platform called Beacon during HoLEP, a common procedure to treat enlarged prostate symptoms. It may help men with difficulty urinating due to an enlarged prostate.
Santiago, Santiago MetropolitanAges 45 years+ - NCT06661122Recruiting
Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Multiple LocationsAges 18 years+ - NCT06659614Recruiting
Prostate tissue collection for future cancer research
This study collects prostate tissue samples from men who are either at higher risk due to a gene change or are getting a biopsy or prostate surgery for routine care. The samples are stored in a biobank for future research on prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,360 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.